New combo pill aims to supercharge cholesterol lowering

NCT ID NCT07619118

Not yet recruiting Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether a new combination pill containing laroprovstat and rosuvastatin lowers LDL cholesterol better than rosuvastatin alone. About 200 adults with high cholesterol and a history of heart disease or high risk will take either the combo or a placebo plus rosuvastatin daily for 8 weeks. The study measures changes in cholesterol levels and checks for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: laroprovstat/rosuvastatin combination pill
What this could lead to: If successful, this combination pill could offer a more effective way to lower LDL cholesterol than current statin therapy alone, potentially reducing heart attack and stroke risk.
What could go wrong: This is an early-stage Phase 3 trial with only 200 participants, so results may not apply to everyone. The combination may cause more side effects than rosuvastatin alone, and it is not a cure—patients would need to take it long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERCHOLESTEROLAEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hypercholesterolemia hypercholesterolemia, familial, 1 hyperlipidemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERCHOLESTEROLAEMIA

More trials for these conditions

Other studies related to the condition(s) this trial covers.